Clinical Trials Updates
Latest updates from ClinicalTrials.gov for your disease states of interest
Filter by Disease State
Filter Clinical Trial Updates
Recent Clinical Trial Updates
Pfizer Initiates Phase 3 Trial for BCMA-targeted Therapy in Multiple Myeloma
NCT05987654 • Updated May 28, 2025
Pfizer has initiated a Phase 3 trial (BCMA-MM-301) evaluating PF-06863135, a BCMA-targeted therapy, in patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy.
CI Team Analysis
This trial positions Pfizer as a direct competitor to our MM-302 program. The trial design includes similar endpoints and patient population, but with a potentially more favorable dosing schedule. Recommend close monitoring of enrollment rates and interim analysis timelines.
Trial Details
Timeline
BMS Completes Enrollment for Deucravacitinib in Adolescent Psoriasis
NCT04876326 • Updated May 24, 2025
Bristol Myers Squibb has completed enrollment for its Phase 3 trial evaluating deucravacitinib (BMS-986165) in adolescent patients with moderate to severe plaque psoriasis. The trial status has changed from "Recruiting" to "Active, not recruiting."
CI Team Analysis
This milestone puts BMS on track for potential adolescent indication approval by Q3 2026, ahead of our projected timeline for similar expansion. The completed enrollment occurred 3 months faster than anticipated, suggesting strong investigator interest and potentially favorable efficacy signals in this population.
Trial Details
Timeline
© 2025 CI Agent. All rights reserved.